1.28
+2.40%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Cellectar Biosciences
From its filings with the US Securities and Exchange Commission
Cellectar Biosciences is based in Florham Park, New Jersey and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker CLRB. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported a net loss of $21.8m. At that date it held total assets of $15.0m and shareholders' equity of $8.5m.
We are a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer. Our core objective is to leverage our proprietary phospholipid ether drug conjugate ™ (PDC™) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and better safety as a result of fewer off-target effects. We believe that our PDC platform possesses the potential for the discovery and development of the next generation of cancer-targeting treatments, and we plan to develop PDCs both independently and through research and development collaborations.
The Company is primarily focused on the development of its radioconjugate PDC programs, also known as phospholipid radioconjugates or PRCs, designed to provide targeted delivery of a radioisotope directly to cancer cells, while limiting exposure to healthy cells. We believe this profile differentiates our PRCs from many traditional on-market treatments and radiotherapeutics. Our three lead programs are: CLR 121125 (CLR 125), an iodine-125 Auger-emitting program, prepared to enter a clinical trial in 2025; CLR 121225 (CLR 225), an actinium-225 based program; and iopofosine I 131 (iopofosine I 131, or simply iopofosine), a beta-emitting iodine-131 based program which has been studied extensively, as described below.
Quoted from its 10-K, filed 4 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 20 May 2005
- Employees
- 11
- Website
- cellectar.com ↗
- Head office
- 100 CAMPUS DRIVE, FLORHAM PARK, NJ, 07932
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Mr. Douglas SwirskyIndependent Chairman of the Board$109,875
- Mr. James CarusoPresident, Chief Executive Officer, Director, since 2015$2.0m
- Mr. Chad KoleanChief Financial Officer, Vice President, Secretary$1.1m
- Mr. Jarrod LongcorChief Operating Officer$1.4m
- Dr. Andrei ShustovSenior Vice President - Medical
- Mr. Shane LeaChief Commercial Officer
- Dr. Asher Alban Chanan-KhanIndependent Director$48,250
- Mr. Frederick DriscollIndependent Director$93,250
- Mr. Stefan LorenIndependent Director$93,250
- Mr. John NeisIndependent Director$93,250
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Company employs 11 full-time employees
- Headquartered in Florham Park, New Jersey
- Develops phospholipid drug conjugates (PDCs) for cancer treatment
Weaknesses
- IPO occurred in 2005-05-20
- Limited employee count of 11
- Pipeline includes only pre-clinical and clinical product candidates
Opportunities
- PDC therapeutic CLR 131 targets cancer cells with iodine-131
- CLR 1900 Series targets solid tumors with mitosis inhibition
- Research and development based on PDC cancer-targeting delivery platform
Threats
- Company is engaged in biotechnology sector with high competition
- No mention of revenue or financial stability
- Dependent on development of PDCs for cancer treatment
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.